The City of Portage, Michigan has acquired a new piece of land, thanks to a unique deal with Pfizer. The company, which previously owned the property on Lovers Lane, has offered to sell it to the city for just $1. The land, which is situated between Stryker Way and Ramona Avenue, is adjacent to properties already owned by the city, making it a prime opportunity for expansion and preservation. Additionally, the property is bordered by Portage Creek, which defines the eastern boundary, and the city already holds an easement along the western edge for the Portage Creek Bicentennial Park Trail.

The city’s acquisition of this land will allow for contiguous ownership along the western edge of Portage Creek, preserving valuable green space and enhancing the community’s stewardship efforts. The city is thrilled to have secured this unique opportunity, and officials praise Pfizer’s “generous offer” and “strong corporate responsibility.” The sale reflects a positive partnership between the city and the corporation, demonstrating that public-private collaborations can lead to mutually beneficial outcomes. With this acquisition, the city will be able to expand its environmental preservation efforts, protecting natural habitats and providing recreational spaces for residents to enjoy.

The Brooklyn Brownstone is a stunning 4,200 square-foot property in Brooklyn, New York that was built by the co-founder of Pfizer, Charles F. Palm. The mansion is currently on the market for a staggering $10.35 million.

The property, which was constructed in the late 19th century, features a blend of Victorian and Italianate architectural styles. The exterior is adorned with intricate details, including ornate brickwork, ornamental tin cornices, and carved wooden shutters. The interior boasts high ceilings, hardwood floors, and stunning chandeliers, creating a luxurious atmosphere.

Upon entering the property, one is immediately struck by the grand foyer, which features a sweeping staircase and a curved balcony overlooking the gracious reception area. The property’s five floors are filled with an impressive array of rooms, including six bedrooms, six bathrooms, and six working fireplaces. The estate also features a generous playroom, a library, and a formal dining room perfect for entertaining.

The property’s architecture is not only aesthetically pleasing but also exudes quality finishes and materials. The property features high-end amenities such as a smart home system, a security system, and a private elevator.

One of the crowning jewels of the property is its outdoor spaces. The rear garden is a tranquil retreat, complete with a private fence, a pool, and a patio area perfect for al fresco dining. The property also features a roof deck offering breathtaking views of the Manhattan skyline.

The location of the property is also a major draw. The Brooklyn Brownstone is situated in one of Brooklyn’s most desirable neighborhoods, surrounded by top-rated schools, parks, and restaurants. The property is also just a short distance from Manhattan, making it an ideal choice for those who want to enjoy the best of both worlds.

With its stunning architecture, luxurious finishes, and desirable location, the Brooklyn Brownstone is an unparalleled opportunity for those seeking a one-of-a-kind home. At $10.35 million, it’s a price tag that’s only for the most discerning buyer.

Pfizer has appointed James List, a former executive from Johnson & Johnson, as its new Chief Internal Medicine Officer to enhance the company’s efforts in obesity drug development. List has a strong background in the pharmaceutical industry, with over 20 years of experience in various leadership roles. He has a deep understanding of the industry, having spent 15 years at Johnson & Johnson, most recently serving as the company’s Vice President, Worldwide Oncology and Inflammation.

As the new Chief Internal Medicine Officer at Pfizer, List will be responsible for leading the company’s efforts in developing and commercializing innovative treatments for a range of diseases, including obesity, which is a significant unmet medical need. Under the leadership of List, Pfizer will delve deeper into using innovative technologies and approaches to develop new treatments for various diseases.

List’s appointment at Pfizer is seen as a significant move to strengthen the company’s capabilities in internal medicine, which is a critical area of focus given the increasing prevalence of chronic diseases worldwide. The move is also expected to boost Pfizer’s research and development efforts, as well as its pipeline of innovative treatments.

Havas, a global advertising holding company, has reported “record results” in its first year as a separate entity, but its net revenue growth of 1.5% to €2,736 million is modest. Organic growth was down 0.8%, likely due to a flat Q4, where many of its rivals, including Publicis, fared better. Small acquisitions accounted for most of the revenue increase.

Geographically, Havas saw growth in Europe (1.2%) and Latin America (14.7%), while North America was down 6.6%. Asia Pacific and Africa saw a 1.1% increase. The company is forecasting 2% growth for the year, ahead of WPP but behind its larger French rival.

Havas CEO Yannick Bolloré attributed the decline in the US to the loss of Pfizer’s business, which spent around $3.3 billion on advertising last year and has consolidated most of its business with Publicis. Creative services, which includes advertising, remains the company’s biggest division, followed by media. Havas also has a significant healthcare business, but this has been impacted by the loss of Pfizer’s business.

As an independent company valued at around €4 billion, Havas is likely to be a takeover or merger target as it lags behind Publicis, which has benefited from deals like the Pfizer account. With its modest growth and loss of significant business, Havas’ future may be uncertain, pending potential consolidation in the industry.

Here is a summary of the article in 400 words:

Pfizer has launched a new AI-powered chatbot called Health Answers by Pfizer, which provides trustworthy information on common health questions. The chatbot uses machine learning models to generate responses derived from “verified sources” and includes citations. The company warns that the responses are not medical advice and there is a risk of bad information reaching users. The chatbot is part of Pfizer’s plan to expand its presence in the direct-to-consumer space through its PfizerForAll portal, which connects users to telehealth providers and offers access to prescription and over-the-counter medications.

The chatbot is currently in a testing phase, and the company has cautioned that the risk of bad information reaching users may be higher when using AI-generated responses. The company has implemented safeguards, including oversight from an independent scientific and technology advisory board, filters to ensure accuracy, and clear disclaimers throughout the platform.

Separately, the Health and Human Services (HHS) leaders are missing the Healthcare Information and Management Systems Society (HIMSS) conference in Las Vegas due to a pause in event travel instituted by the Trump administration. As a result, regulators who were originally scheduled to attend are absent, including at least 28 officials from various health department agencies.

Additionally, there are rumors that the Assistant Secretary for Technology Policy (ASTP), which oversees electronic health record software, data interoperability, and other health IT issues, may be targeted for cuts under the Trump administration’s plan to downsize the government. ASTP was created as an expansion of the role of Micky Tripathi, who led the Office of the National Coordinator for Health Information Technology.

The article also touches on the Department of Justice’s probe into Semler Scientific, a device maker, for possible violations of the False Claims Act, and the concept of “biomarkup,” which refers to how commercial interests can influence the development and use of objective measures of medical status, such as laboratory tests. The author, Ken Mandl, argues that this concept can be applied to the use of artificial intelligence in healthcare, where AI-based revenue cycle tools may push clinicians towards more profitable care pathways.

The author has already nominated Albert Bourla, CEO of Pfizer, for the “Worst Biopharma CEO of 2025” award, citing his company’s recent decision to hire Patrizia Cavazzoni, a former top drug regulator at the Food and Drug Administration (FDA), as its new chief medical officer. The author regards this move as a “dumbest, most damaging corporate screwup” since the infamous “New Coke” rollout.

The criticism stems from the long-standing concerns about the close relationship between the pharmaceutical industry and the FDA, including the practice of hiring former top FDA officials into lucrative executive positions immediately following their departure from government service. This perceived coziness has been a hot topic, with the “Make America Healthy Again” movement and its leader, Robert F. Kennedy Jr., who is also the head of the Department of Health and Human Services, vocally expressing their disapproval.

The author suggests that Bourla’s decision to hire Cavazzoni will only fuel these concerns, potentially damaging the company’s reputation and undermining public trust in the pharmaceutical sector as a whole. The article concludes by leaving the reader to wonder if Bourla’s move was a deliberate attempt to antagonize the public or if it was simply a misguided choice, either way, making him a strong contender for the “Worst Biopharma CEO of 2025” award.

The European Medicines Agency (EMA) has urged Pfizer and Moderna to boost their production volume of COVID-19 vaccines to meet the ongoing demand and supply gaps in the market. The EMA, in a statement, emphasized that the recent surge in COVID-19 cases, particularly in Europe, has put a significant strain on the existing vaccine supplies.

The EMA stated that Pfizer and Moderna, being two of the biggest vaccine manufacturers, should augment their production capacity to ensure timely delivery of vaccines to meet the growing demand. The agency emphasized that this is crucial to prevent the spread of the virus and reduce hospitalizations.

The EMA’s appeal comes as many European countries are struggling to control the surge in COVID-19 cases, with some experiencing a third wave of the pandemic. Many countries are reporting a shortage of vaccines, which is making it challenging for healthcare providers to maintain adequate supplies.

The EMA’s recommendation is based on its monitoring of the vaccine supply and demand situation in Europe, which suggests that the current vaccine production is not keeping pace with the demand. The agency warned that if the situation is not addressed, it could lead to a reduction in vaccine availability, which would have serious implications for public health.

In response to the EMA’s appeal, both Pfizer and Moderna have agreed to increase their production volume. Pfizer has announced plans to increase its monthly production capacity by 80 million doses, while Moderna has pledged to boost its production by 50 million doses.

It is worth noting that the EMA’s appeal is not limited to Pfizer and Moderna alone. The agency has also been working with other vaccine manufacturers, such as Johnson & Johnson, to ensure that there is adequate supply of COVID-19 vaccines. The EMA has also been monitoring the production capacity of other manufacturers, such as AstraZeneca and Novavax, to ensure that they are meeting the demand.

In conclusion, the EMA has urged Pfizer and Moderna to boost their production volume of COVID-19 vaccines to meet the growing demand and supply gaps in the market. The agency’s appeal comes as many European countries are struggling to control the surge in COVID-19 cases and are facing a shortage of vaccines. The move is aimed at preventing the spread of the virus and reducing hospitalizations.